Ann: Proposed issue of securities - ATH, page-12

iminvestor, thanks for your advice, but IMO commercialization of PBT2 is not a delusionary issue. It is in the agreement between Queensland and ATH and it is also mentioned in the last annual report on page 26 as follows:
Antibiotic Resistance
In December 2020, Alterity acquired an exclusive world-wide license from UniQuest, the commercialisation company of The University of
Queensland (UQ), for the development and commercialization of novel zinc ionophore technology to combat antimicrobial resistance in superbugs.
Under the license, Alterity has the rights to develop and commercialise therapies that re-sensitize bacteria to antibiotics. The licensed technology
combines Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. A
published article in the high-impact journal Science Translational Medicine, showed that PBT2 could reverse antibiotic resistance to critical superbugs and demonstrate efficacy in an animal model of sepsis.
molecules as
Then on page 30 they report new patent application for the corresponding 150 molecules as is PBT2: "On August 27, 2021, we filed a PCT application No. PCT/AU2021,050,986 to register a patent that claims an additional 150 novel compounds, all of which modulate biological Zinc for the potential treatment of cancer, neurological diseases and infectious diseases, and is titled “Compounds for and Methods of Treating Diseases”.

The problem with the promised commercialization has been the fact that ATH wanted to do it without spending its cash on this process.
To do something without spending any money is usually delusional but not so if you have an organization to help you. This fund is just to help this kind of company as ATH is. It states:
"The AMR Action Fund expects to invest more than US$1 billion in smaller biotech companies and provide industry expertise to support the clinical development of novel antibiotics"

It is very clear to me that ATH needs something like the help the fund can get to ATH to get PBT2 commercialized. It may be that this will never happen but I believe that it will. How it can happen, is an interesting issue when we have a small listed company with a small MC.

A deal between ATH and the Fund will benefit both.